» Articles » PMID: 37077394

Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35

Overview
Specialty Chemistry
Date 2023 Apr 20
PMID 37077394
Authors
Affiliations
Soon will be listed here.
Abstract

The orphan G protein-coupled receptor 35 (GPR35) is a potential target for the treatment of pain, inflammation, and metabolic diseases. Although many GPR35 agonists have been discovered, research on functional GPR35 ligands, such as fluorescent probes, is still limited. Herein, we developed a series of GPR35 fluorescent probes by conjugating a BODIPY fluorophore to , a known GPR35 agonist. All probes exhibited excellent GPR35 agonistic activity and desired spectroscopic properties, as determined by the DMR assay, bioluminescence resonance energy transfer (BRET)-based saturation, and kinetic binding experiments. Notably, compound showed the highest binding potency and the weakest nonspecific BRET binding signal ( = 3.9 nM). A BRET-based competition binding assay with was also established and used to determine the binding constants and kinetics of unlabeled GPR35 ligands.

Citing Articles

Revolutionizing GPCR-ligand predictions: DeepGPCR with experimental validation for high-precision drug discovery.

Zhang H, Fan H, Wang J, Hou T, Saravanan K, Xia W Brief Bioinform. 2024; 25(4).

PMID: 38864340 PMC: 11167311. DOI: 10.1093/bib/bbae281.


GPR35 acts a dual role and therapeutic target in inflammation.

Wu Y, Zhang P, Fan H, Zhang C, Yu P, Liang X Front Immunol. 2023; 14:1254446.

PMID: 38035084 PMC: 10687457. DOI: 10.3389/fimmu.2023.1254446.

References
1.
Conroy S, Kindon N, Glenn J, Stoddart L, Lewis R, Hill S . Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y Receptor Based on AR-C118925. J Med Chem. 2018; 61(7):3089-3113. PMC: 6026847. DOI: 10.1021/acs.jmedchem.8b00139. View

2.
Hu H, Deng H, Fang Y . Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist. PLoS One. 2012; 7(4):e34934. PMC: 3325260. DOI: 10.1371/journal.pone.0034934. View

3.
Park S, Lee S, Nam S, Im D . GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?. Br J Pharmacol. 2017; 175(1):154-161. PMC: 5740256. DOI: 10.1111/bph.14082. View

4.
Thimm D, Funke M, Meyer A, Muller C . 6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35. J Med Chem. 2013; 56(17):7084-99. DOI: 10.1021/jm4009373. View

5.
Stoddart L, Johnstone E, Wheal A, Goulding J, Robers M, Machleidt T . Application of BRET to monitor ligand binding to GPCRs. Nat Methods. 2015; 12(7):661-663. PMC: 4488387. DOI: 10.1038/nmeth.3398. View